/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for various diseases. With a market cap of $130.5 billion, Regeneron’s operations span various countries in North America, Europe, and Asia.
Companies worth $10 billion or more are generally described as "large-cap stocks," and Regeneron fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the biotechnology industry. The company has a track record of developing new technologies to help discover better and novel antibody medicines.